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osting by EAbstract The preparation anti-D immunoglobulin is an important therapy for both treatment and
protection. Titer of anti-D immunoglobulin preparation is an important factor to determine the
dose of treatment. Many methods are used to evaluate the titer of anti-D immunoglobulin prepa-
ration. One of the new methods developed recently is column agglutination test. To evaluate the
BioVue column agglutination test, it was compared to conventional tube agglutination test using
anti-D immunoglobulin preparations from three different producers, ten lots each. Results showed
that the BioVue column agglutination test is comparable to conventional tube agglutination test but
with much ease. In conclusion, the BioVue column agglutination test is accurate and easy to use in
determination of anti-D titer for quality control purposes.
ª 2010 King Saud University. All rights reserved.1. Introduction
Human Anti-Rh(D) immunoglobulin (anti-D) is a liquid or
freeze-dried preparation containing immunoglobulin, mainlyience, King Khalid University,
l.com
ity. All rights reserved. Peer-
d University.
lsevierimmunoglobulin G. The preparation is intended for intramus-
cular administration. It contains speciﬁc antibodies against
erythrocyte D-antigen and may also contain small quantities
of other blood-group antibodies. Human anti-D immunoglob-
ulin is preferably obtained from the plasma of donors with a
sufﬁcient titer of previously acquired anti-D antibodies (Ph
Eur, 2009). Although anti-Rh(D) was once the major etiology
of haemolytic disease of the fetus and newborn (HDFN), the
widespread adoption of antenatal and postnatal anti-D immu-
noglobulin has resulted in a marked decrease in the prevalence
of alloimmunization due to the Rh(D) antigen present during
pregnancy (Singla et al., 2010). Immune thrombocytopenia
(ITP) is an acquired bleeding autoimmune disorder character-
ized by a markedly decreased blood platelet count. Anti-D has
been successfully used in the setting of both acute and chronic
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venting alloimmunization to the D antigen in other individuals
would allow for the transfusion of D+ blood in an emergency,
continued support with D+ granulocyte concentrates, and
possibly prevent the concomitant formation of autoantibody
(Rosse et al., 1990).
Titration is the common and simple method used in the
routine laboratory to estimate the titer of an antibody (Judd,
2001).
Anti-D immunoglobulin titration can be performed in
tubes, microplates or using microcolumn tests. Coombs et al.
(1945) described the indirect antiglobulin test (IAT), and
Diamond and Abelson (1945) described albumin, as a potenti-
ator for the detection of ‘‘incomplete’’ or IgG antibodies. This
classic saline IAT is still viewed as the gold standard (Rumsey
and Ciesielski, 2000).
Three types of microcolumn tests have been developed: Bio-
Vue Column Agglutination Technology, afﬁnity columns and
glass microcapsules (Lapierre et al., 1990; Walker, 1997).
The BioVue Column Agglutination Technology assay has been
widely used in blood banking in Europe and America since
1991 for direct and indirect antiglobulin tests, ABO/Rh typing,
red blood cell phenotyping, detecting unexpected antibodies,
and for other applications (Lapierre et al., 1990). Its popularity
grew from its standardized performance, technical ease, stable
endpoint and the versatility of the methodology.
The purpose of the current study was to evaluate BioVue
Column Agglutination Technology microcolumn assay for
anti-D immunoglobulin titration in National Control Labora-
tories. The use of such method will facilitate the process of eval-
uating anti-D Ig titer in shorter time with more accurate results.2. Material and methods
2.1. Samples and sample preparation
Ten Rh immune globulin (RhIG) lots each of RhoGAM UF,
WinRho and Rhophylac were used. The WHO international
standard anti-D immunoglobulin, 285 IU/ml (NIBSC Code:
01/572) was used as reference standard. Where 5 IU being
equivalent to 1 lg (Stroncek et al., 2001), all samples and stan-
dard were initially diluted up to titer of 60 lg/ml in phosphate
buffered saline (PBS) containing 2% bovine serum albumin
(BSA, PBS–BSA). Serial twofold dilution of all starting prep-
arations (60 lg/ml) was done up to 1/16,384.
2.2. Red blood cells
According to Ph Eur (2009), Rh-positive blood from ﬁve do-
nors was pooled. These blood samples were kindly provided
by blood bank, Egyptian Holding Company of Bio-Products
and Vaccines. These blood samples were tested for HIV-1/2,
HBsAg, HCV-Ab and syphilis antibody before supplying.
Pooled blood was washed three times in PBS–BSA and then
5% RBCs suspension was prepared.
2.3. Anti-human globulin
Anti-human globulin, anti-IgG, -C3d; polyspeciﬁc (Rabbit and
Murine Monoclonal) (Ortho-Clinical Diagnostics, Raritan,
NJ).2.4. Microcolumn
Ortho BioVue system (poly cassette) was obtained from
Ortho-Clinical Diagnostics. Ortho BioVue system poly cas-
settes (Ortho-Clinical Diagnostics, Raritan, NJ) are comprised
of 6 columns containing a buffered solution with bovine albu-
min and macromolecular potentiators, as well as the preserva-
tives 0.1% (w/v) sodium azide and 0.01 M ethylenediamine
tetraacetic acid (EDTA).
2.5. Tube testing
Serial twofold dilutions were prepared as indicated above and
titration was performed in triplicates according to American
Association of Blood Banks Technical Manual (Vengelen-
Tyler, 1999). Brieﬂy, 100 ll of each serum dilution and 50 ll
of red blood cell suspension were dispensed into each tube
and incubated for 60 min at 37 C. After washing three times
with PBS–BSA, 100 ll of the antihuman globulin was added.
All tubes were examined for agglutination. Signiﬁcant titer is
the last dilution giving positive reaction. Negative result was
as no agglutination of the red blood.
2.6. BioVue column agglutination assay method
For the BioVue Column Agglutination Technology microcol-
umn assay, each 6-column cassette was seated on Ortho Bio-
Vue System Work Rack (Ortho-Clinical Diagnostics,
Raritan, NJ), 50 ll BLISS (Ortho-Clinical Diagnostics, Rari-
tan, NJ) and10 ll of RBCs suspension were added to all col-
umns. Diluted samples in triplicates, 40 ll each, were
dispensed in each corresponding column. The cassettes were
incubated for 10 min in Ortho BioVue Heat Block and were
spinned down for 5 min in Ortho BioVue centrifuge. Follow-
ing centrifugation, the cards were examined for agglutination.
Agglutinated red blood cells become trapped in or above the
column glass beads and unagglutinated red blood cells move
through the glass beads and form a pellet at the bottom. Sig-
niﬁcant titer is the last dilution giving positive reaction. Nega-
tive result was as no agglutination of the red blood and all of
the red blood cells pass through the column glass beads and
form a smooth button at the bottom of the bead column.3. Results
3.1. Tube agglutination test
WHO international standard anti-D immunoglobulin showed
positive agglutination up to dilution 1/4096 with clear negative
reaction (no agglutination) at dilution 1/8192. Anti-D titration
was performed on ten lots of RhoGAM UF product. The
RhoGAM UF product showed positive agglutination up to
dilution between 1/2048 (one lot) and 1/4096 (nine lots) with
clear negative reaction (no agglutination) for all lots at dilution
1/8192. Anti-D titration was performed on ten lots of WinRho
product. WinRho products showed positive agglutination up
to dilution between 1/2048 (one lot) and 1/4096 (nine lots) with
clear negative reaction (no agglutination) for all lots at dilution
1/8192. Anti-D titration was performed on ten lots of Rhophy-
lac product. The product Rhophylac showed positive aggluti-
nation up to dilution between 1/1024 (one lot) and 1/2048
Figure 1 Titration of the product RhoGAM UF using ortho
BioVue system poly cassettes. Microcolumns 1 and 2 showed
positive agglutination (4+), microcolumns 3 and 4 showed 3+
positive agglutination, while microcolumns 5 and 6 showed
negative reaction.
Evaluation of BioVue Column Agglutination Technology 211(nine lots) with clear negative reaction (no agglutination) for
all lots at dilution 1/4096.
3.2. BioVue column agglutination assay
WHO international standard anti-D immunoglobulin showed
positive agglutination up to dilution 1/8192 with clear negative
reaction (all red cells at the bottom of the column) at dilution
1/16,384. The product RhoGAM UF showed positive aggluti-
nation up to dilution between 1/4096 (one lot) and 1/8192
(nine lots) with clear negative reaction for all lots at dilution
1/16,384 (Fig. 1). The product WinRho showed positive agglu-
tination up to dilution between 1/4096 (one lot) and 1/8192
(nine lots) with clear negative reaction for all lots at dilution
1/16,384. The product Rhophylac showed positive agglutina-
tion up to dilution between 1/2048 (one lots) and 1/4096 (nine
lots) with clear negative reaction for all lots at dilution 1/8192.
In all samples tested, the titers by the BioVue Column
Agglutination Technology microcolumn assay were consis-
tently higher than those by the conventional tube test. The ob-
served differences were only twofold.4. Discussion
The titer of human anti-D immunoglobulin preparation is
determined by comparing the quantity of that preparation nec-
essary to produce agglutination of D-positive red blood cells
with the quantity of a reference preparation, calibrated in
international units, required to produce the same effect. Hu-
man anti-D immunoglobulin is calibrated in international
units by comparison with the international standard and in-
tended for use in the assay of human anti-D immunoglobulin
(Ph Eur, 2009).
Anti-D titration is traditionally performed by tube tech-
nique. Variation in results between laboratories is usual
(Moise, 2002). In the time tube agglutination test showed two-fold increase in results, but ﬁnal titer of the sample regarding
to the standard preparation of anti-D still the same. Studies
done by Novartti et al. (2003) also demonstrated that anti-D
titration in the BioVue Column Agglutination Technology
microcolumn assay showed signiﬁcantly higher titers (mean
3.4-fold) than the conventional tube test in all samples studied.
In tube agglutination test many steps before reading the re-
sults are involved including, incubation, wash steps, centrifu-
gation, reconstitution and addition of reagents. Also in Ph.
Eur, assay of human anti-D immunoglobulin, Method A, suit-
able apparatus for automatic continuous analysis, cooling coil
and manifold are used as well as many reagents and reagent
preparations are used. In contrary, BioVue BioVue Column
Agglutination Technology used standardized method sparing
the tedious washing steps which show much lower labor
needed for performing the reaction and less total test time.
Method of reading of the results in tube agglutination test
depends on evaluating RBCs agglutination by naked eye or
by microscope which may involve human error or person-to-
person differences. Techniques for reading and grading reac-
tivity are difﬁcult to learn, and it may be difﬁcult for staff to
maintain competence in low-volume laboratories. The unstable
endpoints for the tube method can make reading, grading, and
interpreting tests almost impossible (Rumsey and Ciesielski,
2000). In Ph. Eur, assay of human anti-D immunoglobulin,
method A, RBCs are ﬁrst lysed and haemoglobin content is
estimated for every specimen. In the time it easy step to per-
form, it need the use of instrument and calculation. Reading
of column is very easy where positive reactions are indicated
by RBC agglutinates trapped anywhere in the column of the
BioVue column. Negative reactions display a pellet of RBCs
on the bottom of the microtube and no agglutinates within
the matrix of the BioVue Column Agglutination Technology
column (Rumsey and Ciesielski, 2000).5. Conclusion
The advantages of the BioVue Column Agglutination Tech-
nology test include small sample size, decreased variation in
volume delivery, greater uniformity between repeat tests, no
cell washing step, and decreased technique dependence. The
BioVue Column Agglutination Technology test has relatively
few steps in the procedure and it provides a clear, easy-to-read,
stable endpoint, so it is easy to learn. When the microtubes are
covered and refrigerated, the BioVue Column Agglutination
Technology cards can be read with accuracy for at least 24 h
after testing. Sensitivity and speciﬁcity of BioVue Column
Agglutination Technology testing have been found to be com-
parable to the tube agglutination test. The BioVue Column
Agglutination Technology test method can replace tube agglu-
tination method and other methods proposed in Ph Eur (2009)
to evaluate the concentration of human anti-D immunoglobu-
lin in national control laboratories as well as producer quality
control laboratories.Acknowledgements
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